《新股表现》亚盛医药(06855.HK)开报53元 高上市价55%
亚盛医药(06855.HK)今日首挂开报53元,较上市价34.2元,高55%,市前成交353.2万股。
亚盛是一间放眼全球的临床阶段生物科技公司,其主要从事开发治疗癌症、乙型肝炎病毒(HBV)及衰老相关疾病的新型疗法。是次来港上市合共发售1,218.09万股,并已引入中生制药(01177.HK)为基石投资者将认购458.64万股;10%公开发售获约751倍超购,已启动回拨机制占比增至50%,认购一手中签率仅9%;股份以招股范围(32.2-34.2元)上限定价,料集资净额近3.12亿元,其中42%将用於研发,将核心产品HQP1351商业化;余下将用作APG-1252、APG-2575、APG-115、APG-1387及APG-2449其他临床计划的持续及规划临床试验等。上市联席保荐人分别为美银美林及花旗。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.